More stories

  • in

    Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

    Source link : https://newshealth.biz/health-news/practice-changing-trial-in-prostate-cancer-shows-benefits-of-perioperative-therapy/ CHICAGO — A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen deprivation therapy (ADT) significantly reduced the risk of metastasis in high-risk localized disease versus ADT alone. After more than 5 years of follow-up, metastasis-free survival (MFS) improved from 73.5% with ADT alone to 78.2% with the addition of the […] […] More

  • in

    Teclistamab Alone Ups Previously Treated Myeloma Survival

    Source link : https://newshealth.biz/health-news/teclistamab-alone-ups-previously-treated-myeloma-survival/ In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma. Medscape Medical News Source link : https://www.medscape.com/viewarticle/teclistamab-alone-ups-previously-treated-myeloma-survival-2026a1000i2u?src=rss Author : Publish date : 2026-05-31 21:55:00 Copyright for syndicated content belongs to the linked Source. The post Teclistamab Alone Ups […] More

  • in

    Trump’s Doc Says President Is in ‘Excellent Health’ as BMI Approaches Obesity Range

    Source link : https://newshealth.biz/health-news/trumps-doc-says-president-is-in-excellent-health-as-bmi-approaches-obesity-range/ Donald Trump’s physician says the president is in “excellent health” and is “fully fit” to serve as commander in chief after a medical exam Tuesday at Walter Reed National Military Medical Center that showed the president’s body mass index (BMI) approaching the obesity range. A report from Sean Barbabella, DO, released late Friday, says Trump […] […] More

  • in

    Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

    Source link : https://newshealth.biz/health-news/upfront-ivonescimab-plus-chemo-bests-pd-1-inhibitor-combo-in-advanced-nsclc/ CHICAGO — A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung cancer (NSCLC), according to the HARMONi-6 trial. At a median follow-up of 21.4 months, the ivonescimab-chemotherapy combination in the first line reduced the risk of death by 34%, with […] […] More

  • in

    ‘The Light Goes Out of Their Eyes in About 3 Years’: What We Heard This Week

    Source link : https://newshealth.biz/health-news/the-light-goes-out-of-their-eyes-in-about-3-years-what-we-heard-this-week/ “The light goes out of their eyes in about 3 years. This is not what they signed up for.” — Clark Coler, MD, of Swedish Medical Group in Seattle, on young physicians facing the increasingly profit-driven demands of modern healthcare. “They feel relief, not pleasure, not joy, just relief.” — Daniel Watter, EdD, of the […] […] More

  • in

    Will PROTEUS Change the Playbook for Radical Prostatectomy?

    Source link : https://newshealth.biz/health-news/will-proteus-change-the-playbook-for-radical-prostatectomy/ New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy. Medscape Medical News Source link : https://www.medscape.com/viewarticle/will-proteus-change-playbook-radical-prostatectomy-2026a1000i2k?src=rss Author : Publish date : 2026-05-31 19:07:00 Copyright for syndicated content belongs to the linked Source. The post Will PROTEUS Change the Playbook for Radical Prostatectomy? first appeared on News Health. —- Author […] More

  • in

    Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma

    Source link : https://newshealth.biz/health-news/abemaciclib-poised-to-be-new-standard-of-care-in-aggressive-liposarcoma/ CHICAGO — Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to the SARC041 trial. Patients (n=108) in the phase IIII study had recurrent or metastatic dedifferentiated liposarcoma (DDLS) that had been treated with any number of prior lines of […] […] More

  • in

    ‘Immediately Practice-Changing’ Lung Cancer Trial in Curative Setting

    Source link : https://newshealth.biz/health-news/immediately-practice-changing-lung-cancer-trial-in-curative-setting/ CHICAGO — The adjuvant treatment of RET fusion-positive non-small-cell lung cancer (NSCLC) following potentially curative surgery or radiotherapy has a new standard of care, researchers reported here. In a phase III study of patients who underwent definitive therapy for stage II-IIIA disease, event-free survival (EFS) at 2 years reached 92% with the oral RET inhibitor […] […] More

  • in

    Top-risk prostate most cancers sufferers take pleasure in perioperative apalutamide treatment

    Source link : https://health365.info/top-risk-prostate-most-cancers-sufferers-take-pleasure-in-perioperative-apalutamide-treatment/ Top-risk localized and in the community complicated prostate most cancers sufferers handled with apalutamide – a subsequent technology neoadjuvant androgen-receptor pathway inhibitor (ARPI) – plus hormone treatment earlier than and after prostate most cancers surgical treatment resulted in additional main pathologic responses and diminished the chance of metastasis or loss of life, assembly each number one […] More

  • in

    Who’s to Say That Medication Is Too Risky?

    Source link : https://newshealth.biz/health-news/whos-to-say-that-medication-is-too-risky/ Peptides have moved from bodybuilding forums into the cultural mainstream. Telehealth clinics advertise them for weight loss and recovery, often outside any FDA-approved indication. Podcasters describe their personal protocols to audiences of millions. HHS Secretary Robert F. Kennedy Jr. has spoken openly about using them himself. To regulators and much of the medical establishment, this […] […] More

  • in

    Abemaciclib Slows Progression of Advanced Liposarcoma

    Source link : https://newshealth.biz/health-news/abemaciclib-slows-progression-of-advanced-liposarcoma/ In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold. Medscape Medical News Source link : https://www.medscape.com/viewarticle/abemaciclib-slows-progression-advanced-liposarcoma-2026a1000i2g?src=rss Author : Publish date : 2026-05-31 16:30:00 Copyright for syndicated content belongs to the linked Source. The post Abemaciclib Slows Progression of Advanced Liposarcoma first appeared on News Health. —- […] More

  • in

    Predictive type is helping tailor PSMA remedy for prostate most cancers sufferers

    Source link : https://health365.info/predictive-type-is-helping-tailor-psma-remedy-for-prostate-most-cancers-sufferers/ A brand new machine-learning way for prostate-specific membrane antigen (PSMA) remedy of metastatic castration-resistant prostate most cancers (mCRPC) may just estimate radiation dose to tumors and wholesome organs prior to remedy starts. The use of information already to be had from pre-therapy PET/CT scans, this novel prediction instrument may just assist personalize remedy plans, make stronger […] More

Load More
Congratulations. You've reached the end of the internet.